Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung

Abstract Background Alectinib is a highly selective tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK) and provided a significantly prolonged progression-free survival compared with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) harboring rearrangements of the A...

Full description

Bibliographic Details
Published in:Surgical Case Reports
Main Authors: Naoko Imanishi, Kazue Yoneda, Akihiro Taira, Yoshinobu Ichiki, Naoko Sato, Masanori Hisaoka, Fumihiro Tanaka
Format: Article
Language:English
Published: Japan Surgical Society 2018-03-01
Subjects:
ALK
Alectinib
Pathologic response
Adenocarcinoma
Lung
Online Access:http://link.springer.com/article/10.1186/s40792-018-0430-7

Internet

http://link.springer.com/article/10.1186/s40792-018-0430-7

Similar Items